Clinical Study Report Synopsis Section
ICH E3 and its FDA-hosted Q&A treat the synopsis as a stand-alone summary of the study that includes design, key methods, study population/disposition, important deviations, and central efficacy and safety results. Use the governing ICH/regulatory submission framework. A CSR synopsis is not the same artifact as a journal abstract, and length/content expectations can vary with study complexity.
A Clinical Study Report Synopsis section lets a reviewer understand the study’s design, population, key conduct information, and main efficacy/safety findings without reading the full CSR first.
Key details
Important caveats
Scope Boundary
Use the governing ICH/regulatory submission framework. A CSR synopsis is not the same artifact as a journal abstract, and length/content expectations can vary with study complexity.
Further guidance
Content
Keep it concise but self-contained; include the critical design/method/result information needed to interpret the study rather than merely repeating the abstract or table of contents.
Purpose
A Clinical Study Report Synopsis section lets a reviewer understand the study’s design, population, key conduct information, and main efficacy/safety findings without reading the full CSR first.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E3 Structure and Content of Clinical Study Reports (opens in a new tab)U.S. Food and Drug Administration · FDA-hosted ICH E3 guidance defining the structure and content of a core clinical study report
- E3 Structure and Content of Clinical Study Reports — Questions and Answers (R1) (opens in a new tab)U.S. Food and Drug Administration · FDA-hosted ICH E3 questions and answers clarifying the CSR synopsis and core report implementation